Literature DB >> 10861575

The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation.

J Lüttges1, S Schemm, I Vogel, J Hedderich, B Kremer, G Klöppel.   

Abstract

Tumour grade is one of the prognostic factors in pancreatic ductal adenocarcinoma, but its value is controversial. In this study, the predictive value and the reproducibility of the WHO grading system were reconsidered and the possibility of supplementing it with the immunohistochemically assessed proliferative activity was investigated. Seventy resected ductal adenocarcinomas of the head of the pancreas were evaluated. A total of 60 HPF fields on two to four sections per tumour were screened for glandular differentiation, mucin production, mitosis, and nuclear atypia by two observers with different degrees of experience. Each criterion was scored and the grade was calculated from the mean value of all single scores. Corresponding slides were immunohistochemically stained with the proliferation marker Ki-S5. The percentage of positive nuclei was assessed and a proliferation index (PI) assigned (<10%=1; 10-50%=2; >50%=3). Multivariate analysis (Cox regression) identified grade and R stage as the most significant factors for predicting survival. The PI determined on the basis of Ki-S5 staining did not prove to be an independent prognostic factor. In 30 of 70 carcinomas, it correlated with the tumour grade. Within a given tumour grade, the cases with the least favourable prognosis could be distinguished on the basis of their PI. The inter-observer variability was considerable, with the main differences occurring in the group of G1 tumours. According to the refined WHO criteria, the histopathological grade of pancreatic ductal carcinoma is an important independent prognostic factor, but reproducibility depends on the expertise of the observer. Criteria that relate to cellular and structural differentiation seem to be more predictive than those related to proliferation. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861575     DOI: 10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  36 in total

1.  Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma.

Authors:  Guang-Hui Zhu; Chen Huang; Zheng-Jun Qiu; Jun Liu; Zhi-Hua Zhang; Ning Zhao; Zheng-Zhong Feng; Xiu-Hong Lv
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

2.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

3.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival.

Authors:  Edlyn Soeth; Urte Grigoleit; Barbara Moellmann; Christian Röder; Bodo Schniewind; Bernd Kremer; Holger Kalthoff; Ilka Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-01       Impact factor: 4.553

4.  Mixed ductal-endocrine carcinomas of the pancreas and ductal adenocarcinomas with scattered endocrine cells: characterization of the endocrine cells.

Authors:  N Ohike; A Jürgensen; M Pipeleers-Marichal; G Klöppel
Journal:  Virchows Arch       Date:  2003-02-06       Impact factor: 4.064

5.  Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation.

Authors:  N Hiraoka; Y Ino; S Sekine; H Tsuda; K Shimada; T Kosuge; J Zavada; M Yoshida; K Yamada; T Koyama; Y Kanai
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

6.  Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.

Authors:  Kevin A Maupin; Arkadeep Sinha; Emily Eugster; Jeremy Miller; Julianna Ross; Vincent Paulino; Venkateshwar G Keshamouni; Nhan Tran; Michael Berens; Craig Webb; Brian B Haab
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

7.  Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival.

Authors:  David F Schaeffer; Daniel R Owen; Howard J Lim; Andrew K Buczkowski; Stephen W Chung; Charles H Scudamore; David G Huntsman; Sylvia S W Ng; David A Owen
Journal:  BMC Cancer       Date:  2010-02-23       Impact factor: 4.430

8.  Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.

Authors:  Yusuke Ohara; Tatsuya Oda; Masato Sugano; Shinji Hashimoto; Tsuyoshi Enomoto; Keiichi Yamada; Yoshimasa Akashi; Ryoichi Miyamoto; Akihiko Kobayashi; Kiyoshi Fukunaga; Yukio Morishita; Nobuhiro Ohkohchi
Journal:  Cancer Sci       Date:  2013-06-24       Impact factor: 6.716

9.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Authors:  Bence Sipos; Simone Möser; Holger Kalthoff; Virag Török; Matthias Löhr; Günter Klöppel
Journal:  Virchows Arch       Date:  2003-04-12       Impact factor: 4.064

10.  High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.

Authors:  Annika Lehmann; Carsten Denkert; Jan Budczies; Ann-Christin Buckendahl; Silvia Darb-Esfahani; Aurelia Noske; Berit Maria Müller; Marcus Bahra; Peter Neuhaus; Manfred Dietel; Glen Kristiansen; Wilko Weichert
Journal:  BMC Cancer       Date:  2009-11-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.